{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035391","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.424845+00:00","generated_at":"2026-05-30T00:32:25.841203+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine","bullets":["Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).","Cash totaled $5.6M as of Sep 30, 2024, down from $23.4M at Dec 31, 2023.","108 patients have completed 1 year of treatment in brilaroxazine OLE trial; topline data expected December 2024.","NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026; RECOVER-2 start expected Q1 2025 pending financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035391","json":"https://secwatch.observer/filing/0001437749-24-035391.json","markdown":"https://secwatch.observer/filing/0001437749-24-035391.md","text":"https://secwatch.observer/filing/0001437749-24-035391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/0001437749-24-035391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/rvph20241107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:32:25.841203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}